CONDROSULF cps 60x 400mg (2pcs)

These articles cannot be delivered for legislative reasons to the following countries:

Slovakia

Application form	tablets, capsules
Indication group	antiarthrotics antirheumatics
Manufacturer	IBSA Institut Biochimique SA, Lugano, Switzerland, www.ibsa.ch
Active substance	Chondroitini sulfas a natricus 400 mg
minimum amount for dispatch	CONDROSULF cps : Chondroitinsulphate is one of the main parts of the cartilage intercellular mass, and it has a significant characteristic ability to bind water in tissues. Thus it secures the mechanical and elastic properties of cartilage. In arthritic degenerative processes, the content of chondroitinsulphate in cartilage decreases by the effect of specific lytic enzymes. In consequence of the reduced ability to bind water, the gradual cartilage degeneration and deterioration of the joint function deterioration occurs. Administration of Condrosulf 400 leads to renewal of the metabolic balance of chondrocytes by supplying the chondroitinsulphate. The preparation is used in degenerative joint diseases, especially in gonarthrosis, coxarthrosis and in finger joint arthrosis. The preparation is intended for adult patients.
Summary of product characteristics SHOW	Information on a drug is available on the official website: Medicines.org.uk or EMEA : European Medicines Agency
SUKL	CONDROSULF 400 cps 60x400mg -